What is the 13F Pro Quality Score for YDES?

13F Pro ranks YD Bio Ltd (YDES) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View YDES's current score at https://13fpro.ai/company/YDES (free sign-up required for the full ranking).

Which hedge funds own the most YDES stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of YDES include Cypress Capital Management (WY), Oasis Management Co Ltd., Garrett Wealth Advisory Group,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/YDES as soon as new 13F filings post.

Where does 13F Pro source YDES data?

All YD Bio Ltd fundamentals and ownership data come directly from SEC EDGAR. YD Bio Ltd files with the SEC under CIK 2011674. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is YDES in?

YD Bio Ltd (YDES) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is YDES research updated on 13F Pro?

YDES's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

YD Bio Ltd(YDES)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 2011674 YDES stock profile & AI dashboard →

13F Pro Quality Score

24.7/100

Rank #2,682 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why YDES Scores 25/100

exact factor attribution · 2026-09-11

YDES's composite is driven by shareholder dilution, held back by free cash flow and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Shareholder dilution

+2.2 pts

95th pct

Institutional flow

+0.5 pts

59th pct

Earnings growth

-1.0 pts

30th pct

Earnings quality

-2.0 pts

30th pct

Scale

-3.0 pts

30th pct

Revenue growth

-4.0 pts

30th pct

Capital efficiency

-4.2 pts

8th pct

Profitability

-6.8 pts

5th pct

Free cash flow

-6.9 pts

4th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

YDES Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for YD Bio Ltd (YDES), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores YDES at 24.7/100 on a 32-signal composite quality model, placing it at rank #2,682 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (FY 2025), YD Bio Ltd reports quarterly revenue of $596.8K, net income of $-8.3M, free cash flow of $-8.0M. Top institutional holders of YDES by reported 13-F value include Cypress Capital Management (WY), Oasis Management Ltd., Garrett Wealth Advisory Group, based on the most recent SEC filings. YDES trades on the Nasdaq exchange and files with the SEC under CIK 2011674. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate YDES daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for YD Bio Ltd directly from SEC EDGAR.

Revenue

FY 2025

$596.8K

Net Income

FY 2025

$-8.3M

Free Cash Flow

FY 2025

$-8.0M

D/E Ratio

FY 2025

0.00

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+16.9% YoY

$596.8KFY 2025

FY22 —FY23 $350.1KFY24 $510.4KFY25 $596.8K

Net Income

-488.8% YoY

$-8.3MFY 2025

FY22 —FY23 $13.6KFY24 $-1.4MFY25 $-8.3M

Operating Income

-260.6% YoY

$-5.3MFY 2025

FY22 —FY23 $-9.8KFY24 $-1.5MFY25 $-5.3M

EPS (Diluted)

-500.0% YoY

$-0.12FY 2025

FY22 —FY23 $0.00FY24 $-0.02FY25 $-0.12

Total Assets

+100.7% YoY

$13.8MFY 2025

FY22 —FY23 —FY24 $6.9MFY25 $13.8M

Total Debt

$6.8KFY 2025

FY22 —FY23 —FY24 —FY25 $6.8K

Op. Cash Flow

-439.5% YoY

$-6.6MFY 2025

FY22 —FY23 $-55.7KFY24 $-1.2MFY25 $-6.6M

Free Cash Flow

-519.4% YoY

$-8.0MFY 2025

FY22 —FY23 $-55.9KFY24 $-1.3MFY25 $-8.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022
Revenue	$596.8K +16.9%	$510.4K +45.8%	$350.1K	—
Net Income	$-8.3M -488.8%	$-1.4M -10509.7%	$13.6K	—
Operating Income	$-5.3M -260.6%	$-1.5M -14746.5%	$-9.8K	—
EPS (Diluted)	$-0.12 -500.0%	$-0.02	$0.00	—
Total Assets	$13.8M +100.7%	$6.9M	—	—
Total Debt	$6.8K	—	—	—
Operating Cash Flow	$-6.6M -439.5%	$-1.2M -2096.8%	$-55.7K	—
Free Cash Flow	$-8.0M -519.4%	$-1.3M -2219.3%	$-55.9K	—

AI Insight: YDES Financial Trends

Insufficient financial data to assess operational trends; equity deteriorated from $7M to negative $3M in one year.

• Equity swung from $7M (Q4 2024) to negative $3M (Q4 2025), indicating accumulated losses exceeded contributed capital.

⚠ No revenue, net income, operating income, or cash flow data reported across all periods—stage of maturity unclear.

⚠ Negative shareholder equity in latest quarter signals balance sheet stress; funding requirements or restructuring risk.

AI Insight: YDES Ratio Trends

Insufficient financial data to assess YD Bio's operational or capital efficiency trends.

• All key metrics (OpMargin, NPM, ROE, ROA, ROIC, D/E) are missing across all periods from Q4 2022 through Q4 2025.

⚠ No profitability, return, or leverage data available for analysis. Verify data completeness before drawing conclusions on company health.

Get alerted when YDES's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for YD Bio Ltd including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of YDES

Cypress Capital Management LLC (WY)
$1.4M4,644,452 sh
Oasis Management Co Ltd.
$225.0K100,000 sh
Garrett Wealth Advisory Group, LLC
$190.4K84,630 sh
GEODE CAPITAL MANAGEMENT, LLC
$141.1K62,714 sh
Cerity Partners LLC
$99.2K320,089 sh
Cypress Capital Management LLC (WY)
$75.8K33,690 sh
Cerity Partners LLC
$72.9K32,406 sh
True North Advisors, LLC
$68.5K220,819 sh
CITADEL ADVISORS LLC
$67.7K30,106 sh
JANE STREET GROUP, LLC
$48.2K21,423 sh

Fund	Value	Shares
Cypress Capital Management LLC (WY)	$1.4M	4,644,452
Oasis Management Co Ltd.	$225.0K	100,000
Garrett Wealth Advisory Group, LLC	$190.4K	84,630
GEODE CAPITAL MANAGEMENT, LLC	$141.1K	62,714
Cerity Partners LLC	$99.2K	320,089
Cypress Capital Management LLC (WY)	$75.8K	33,690
Cerity Partners LLC	$72.9K	32,406
True North Advisors, LLC	$68.5K	220,819
CITADEL ADVISORS LLC	$67.7K	30,106
JANE STREET GROUP, LLC	$48.2K	21,423

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put YDES on your watchlist

Track score changes the day YD Bio Ltd files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is YDES a good stock to buy?

13F Pro's AI-powered analysis of YD Bio Ltd (YDES) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for YDES are available on the YDES stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. YDES is classified as a small company.

Which hedge funds own YDES?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling YDES. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of YD Bio Ltd's investment landscape.